Castle Biosciences to acquire AltheaDx for $65M upfront plus up to $75M in milestones

CASTLE BIOSCIENCES INC

Upfront consideration: $32.5M cash + $32.5M stock; milestone payments up to $75M tied to 2022-2024 revenue and Medicare coverage.
AltheaDx had <$1M revenue in 2021; its IDgenetix test focuses on mental health pharmacogenomics.
Expected Q2 2022 close; subject to AltheaDx stockholder approval and other customary conditions.
CEO Derek Maetzold and Chairman Daniel Bradbury are AltheaDx directors and beneficial owners, creating related-party transactions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.